Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp ...

EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...

Novo Nordisk and Eli Lilly are both raking in billions from their blockbuster weight loss drugs that are also approved to ...

Are you a print subscriber? Activate your account. By Garett Sloane - 3 min 8 sec ago By Ewan Larkin - 8 min 31 sec ago By ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

Polen Capital, an investment management company, released its “Polen Global Growth Strategy” third-quarter 2024 investor ...

Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong. See why I believe we are at ...

Omega Therapeutics is halting work on its only clinical-stage candidate as part of a strategic refocus centered on three ...

Correspondent Jon Wertheim revisits 60 Minutes' coverage of former mobile giant Nokia and discusses potential risks for the ...

Novo Nordisk, the pharma giant behind Ozempic and Wegovy, has surprising love story origins. The founders, a married couple, ...

After rising in premarket trading, Novo Nordisk's U.S.-listed shares fell after the market opened Wednesday as its ...